Insider Transactions in Q1 2020 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q1 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2020
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.04%
|
$46,500
$465.94 P/Share
|
|
Mar 10
2020
|
George Yancopoulos President and Chief Scientific |
SELL
Open market or private sale
|
Direct |
117,815
-0.81%
|
$55,726,495
$473.68 P/Share
|
|
Mar 09
2020
|
George Yancopoulos President and Chief Scientific |
SELL
Payment of exercise price or tax liability
|
Direct |
128,921
-9.6%
|
$61,366,396
$476.42 P/Share
|
|
Mar 09
2020
|
George Yancopoulos President and Chief Scientific |
BUY
Exercise of conversion of derivative security
|
Direct |
246,736
+15.48%
|
$7,402,080
$30.63 P/Share
|
|
Mar 09
2020
|
Joseph L Goldstein Director |
SELL
Open market or private sale
|
Direct |
2,000
-2.06%
|
$948,000
$474.28 P/Share
|
|
Mar 09
2020
|
Joseph L Goldstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+14.66%
|
$66,000
$33.42 P/Share
|
|
Mar 09
2020
|
Sanofi |
SELL
Open market or private sale
|
Direct |
128,914
-0.63%
|
$63,038,946
$489.65 P/Share
|
|
Feb 27
2020
|
Neil Stahl EVP Research and Development |
SELL
Open market or private sale
|
Direct |
10,349
-2.23%
|
$4,667,399
$451.97 P/Share
|
|
Feb 26
2020
|
George L Sing Director |
SELL
Open market or private sale
|
Indirect |
2,400
-8.34%
|
$1,084,800
$452.83 P/Share
|
|
Feb 26
2020
|
George L Sing Director |
SELL
Open market or private sale
|
Direct |
2,500
-2.12%
|
$1,150,000
$460.0 P/Share
|
|
Feb 26
2020
|
George L Sing Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+2.08%
|
$82,500
$33.42 P/Share
|
|
Feb 26
2020
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
14,651
-40.27%
|
$6,607,601
$451.89 P/Share
|
|
Feb 26
2020
|
Neil Stahl EVP Research and Development |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+40.73%
|
$1,300,000
$52.03 P/Share
|
|
Feb 26
2020
|
Daniel P Van Plew EVP & General Mgr Industrial O |
SELL
Open market or private sale
|
Direct |
15,642
-4.2%
|
$7,117,110
$455.99 P/Share
|
|
Feb 26
2020
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
200
-0.1%
|
$91,000
$455.99 P/Share
|
|
Feb 26
2020
|
Neil Stahl EVP Research and Development |
SELL
Bona fide gift
|
Direct |
750
-3.45%
|
-
|
|
Feb 25
2020
|
Daniel P Van Plew EVP & General Mgr Industrial O |
SELL
Payment of exercise price or tax liability
|
Direct |
17,093
-28.03%
|
$7,640,571
$447.3 P/Share
|
|
Feb 25
2020
|
Daniel P Van Plew EVP & General Mgr Industrial O |
BUY
Exercise of conversion of derivative security
|
Direct |
32,735
+34.93%
|
$982,050
$30.63 P/Share
|
|
Feb 25
2020
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
214
-0.08%
|
$95,872
$448.67 P/Share
|
|
Feb 25
2020
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
800
-3.06%
|
$357,600
$447.3 P/Share
|
|
Feb 25
2020
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+3.68%
|
$272,000
$272.7 P/Share
|
|
Feb 24
2020
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
786
-3.03%
|
$319,116
$406.59 P/Share
|
|
Feb 24
2020
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+3.71%
|
$272,000
$272.7 P/Share
|
|
Feb 24
2020
|
Michael S Brown Director |
SELL
Open market or private sale
|
Direct |
2,000
-40.21%
|
$838,000
$419.01 P/Share
|
|
Feb 24
2020
|
Michael S Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+43.08%
|
$546,000
$273.67 P/Share
|
|
Feb 24
2020
|
George Yancopoulos President and Chief Scientific |
SELL
Open market or private sale
|
Direct |
118,123
-18.58%
|
$49,611,660
$420.17 P/Share
|
|
Feb 13
2020
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
14,279
-41.91%
|
$5,697,321
$399.58 P/Share
|
|
Feb 13
2020
|
Marc Tessier Lavigne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,279
+43.89%
|
$771,066
$54.01 P/Share
|
|
Feb 13
2020
|
Neil Stahl EVP Research and Development |
SELL
Open market or private sale
|
Direct |
10,278
-11.84%
|
$4,131,756
$402.12 P/Share
|
|
Feb 13
2020
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
107
-0.07%
|
$42,907
$401.79 P/Share
|
|
Feb 12
2020
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
14,722
-40.47%
|
$5,918,244
$402.34 P/Share
|
|
Feb 12
2020
|
Neil Stahl EVP Research and Development |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+40.73%
|
$1,300,000
$52.03 P/Share
|
|
Feb 12
2020
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
393
-1.54%
|
$157,986
$402.34 P/Share
|
|
Feb 12
2020
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+1.93%
|
$136,000
$272.7 P/Share
|
|
Feb 07
2020
|
Joseph L Goldstein Director |
SELL
Open market or private sale
|
Direct |
1,000
-9.4%
|
$382,000
$382.83 P/Share
|
|
Jan 03
2020
|
P Roy Vagelos Director |
SELL
Bona fide gift
|
Indirect |
564
-0.39%
|
-
|